Metabolic and blood sugar effects of Orforglipron, a GLP-1 receptor drug, in adults with and without diabetes: A combined analysis of clinical trials

Orforglipron (OFG) is being evaluated across five doses (3, 12, 24, 36, and 45 mg) for its effects on body weight and glycemic outcomes in adults with or without type 2 diabetes mellitus.

• The analysis focuses on dose-response effects of OFG on body weight-related parameters.
• Glycemic outcomes associated with OFG treatment are also being examined.
• Outcomes are tracked over 12, 26, and 36 weeks.
• The study aims to clarify the potential benefits of OFG for managing T2DM and obesity.

Simplified